Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized study of tipifarnib versus best supportive care (including hydroxyurea) in the treatment of newly diagnosed acute myeloid leukemia (AML) in subjects 70 years or older (Farnesyl transferase Inhibition Global Human trials AML 301 [F.I.G.H.T. AML 301])

X
Trial Profile

A randomized study of tipifarnib versus best supportive care (including hydroxyurea) in the treatment of newly diagnosed acute myeloid leukemia (AML) in subjects 70 years or older (Farnesyl transferase Inhibition Global Human trials AML 301 [F.I.G.H.T. AML 301])

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 02 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tipifarnib (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms FIGHT-AML-301
  • Sponsors Janssen Research & Development; Janssen-Cilag
  • Most Recent Events

    • 27 Mar 2019 This trial has been completed in Ireland, according to European Clinical Trials Database.
    • 27 Apr 2010 Actual number of patients (457) added as reported by ClinicalTrials.gov.
    • 19 Sep 2008 Status changed from active, no longer recruiting to completed, reported by ClinicalTrials.gov.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top